Abstract 5331
Background
Ra-223 demonstrated a significant overall survival benefit and favourable safety profile in mCRPC in the ALSYMPCA study (Parker C et al. N Engl J Med 2013; 369:213–223). PARABO (NCT02398526) is an ongoing, prospective, observational, non-interventional, single-arm study with a primary objective to evaluate pain response in mCRPC pts treated with Ra-223 in a real-world setting.
Methods
The aim of this interim analysis was to assess the impact of Ra-223 on pain response, with and without the use of opioids. Pain response was determined by the worst pain item on the Brief Pain Inventory–Short Form (BPI-SF) questionnaire. A clinically meaningful pain response was defined as an improvement of ≥ 2 points; a 95% exact (Clopper–Pearson) confidence interval was reported.
Results
Of the 346 pts enrolled, 311 were included in the interim safety analysis set, 49% of whom used opioids at any time in the study. At baseline (BL), 185/311 (59.5%) had an ECOG performance status of 1 and 222/304 (73.0%) had ≥6 metastatic lesions (but not a superscan). Lumbar vertebrae, pelvis and thigh were amongst the most frequently reported areas of most pain at BL. During the observation period after Ra-223 treatment, 126/211 (59.7%) pts had a clinically meaningful pain response. Of the pts who used opioids vs those who did not, 62/113 (54.9%) vs 64/98 (65.3%) had a clinically meaningful pain response, and 28/110 (25.5%) vs 19/127 (15.0%) achieved almost complete relief after the third dose of Ra-223, respectively.Table:
860P
Ra-223 without opioid use (n = 160) | Ra-233 with opioid use (n = 151) | All pts (N = 311) | |
---|---|---|---|
BPI-SF change ≥2 at observation,* % (95% CI) | (n = 98) 65.3 (55.0–74.6) | (n = 113) 54.9 (45.2–64.3) | (n = 211) 59.7 (52.8–66.4) |
Pain relief due to pain medications** at third Ra-223 dose,‡ % 0%–20% (no relief) 30%–70% (some relief) 80%–100% (almost complete relief) Missing data | (n = 127) 31.5 25.2 15.0 28.4 | 17.3 47.3 25.5 10.0 | 24.9 35.4 19.8 19.8 |
QoL-Set-Pain-Response (n = 211);
**QoL-Set-BPI-SF (n = 269); †This time point was chosen due to limited study numbers at later doses;
‡According to patients’ answer to the question “In the last 24 hours, how much relief have pain treatments or medications provided?” in the BPI-SF questionnaire.
Conclusions
In this study, reflective of real clinical practice, the majority (73.0%) of pts had multiple lesions at BL and almost half (49%) used opioids. Over half (59.7%) of pts reported a decrease in worst pain after Ra-223 treatment, irrespective of opioid use. Of pts who used vs did not use opioids, 54.9% vs 65.3% achieved a clinically meaningful pain response. Overall, a fifth (19.8%) of pts achieved almost complete relief after the third dose of Ra-223.
Clinical trial identification
NCT02398526.
Editorial acknowledgement
Jenny Feehan of OPEN Health Medical Communications (London, UK), with financial support from Bayer.
Legal entity responsible for the study
Bayer Pharma AG.
Funding
Bayer Pharma AG.
Disclosure
H. Palmedo: Honoraria (self), Travel / Accommodation / Expenses: Bayer Pharmaceuticals. S. Eschmann: Honoraria (self), Travel / Accommodation / Expenses: Bayer Pharmaceuticals. A. Werner: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bayer Pharmaceuticals; Advisory / Consultancy: Novartis. I. Selinski: Honoraria (self), Travel / Accommodation / Expenses: Bayer Pharmaceuticals. M. Möllers: Honoraria (self), Travel / Accommodation / Expenses: Bayer Pharmaceuticals. J. Kalinovsky: Full / Part-time employment: Bayer Pharmaceuticals. A. Benson: Full / Part-time employment: Bayer Pharmaceuticals. All other authors have declared no conflicts of interest.
Resources from the same session
5383 - A pilot trial to investigate the impact of a personalised self-management lifestyle programme using mobile technology on the health and wellbeing of cancer survivors
Presenter: Mary Grace Kelly
Session: Poster Display session 3
Resources:
Abstract
5084 - The BRIGHTLIGHT national survey of the impact of specialist teenage and young adult cancer care on caregivers’ information and support needs
Presenter: Rachel Taylor
Session: Poster Display session 3
Resources:
Abstract
4328 - Life beyond cancer: Occupational health care service support in returning work experienced by cancer survivals
Presenter: Minna Nurmi
Session: Poster Display session 3
Resources:
Abstract
3337 - Investigating the factors related to primary caregivers' burden in oncology patients in Greece
Presenter: Ourania Govina
Session: Poster Display session 3
Resources:
Abstract
3387 - Factors Influencing the Level of Emotional Support from Nurses Perceived by Patients Undergoing Haematopoietic Stem Cell Transplantation in Protective Isolation
Presenter: Michela Piredda
Session: Poster Display session 3
Resources:
Abstract
935 - Progressive Muscle Relaxation and Guided Imagery Techniques and the Way of Coping of Parents of Children with Malignancies: A randomized controlled trial
Presenter: Tsitsi Theologia
Session: Poster Display session 3
Resources:
Abstract
3457 - Pharmacist and Nurse Led Melanoma Immunotherapy Clinic
Presenter: Dharmisha Chauhan
Session: Poster Display session 3
Resources:
Abstract
5160 - Measuring the impact of the Irish Cancer Society's Cancer Information Services
Presenter: Aileen McHale
Session: Poster Display session 3
Resources:
Abstract
4297 - It's Great to Talk
Presenter: Noreen Andersen
Session: Poster Display session 3
Resources:
Abstract
4444 - Impact of Burn-Out Syndrome in Oncology personnel and its improvement through specific interventions
Presenter: Inmaculada Ortega
Session: Poster Display session 3
Resources:
Abstract